验证数据展示
经过测试的应用
| Positive FC detected in | PHA treated human PBMCs |
推荐稀释比
| 应用 | 推荐稀释比 |
|---|---|
| Flow Cytometry (FC) | FC : 5 ul per 10^6 cells in a 100 µl suspension |
| This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 5 ul per 10^6 cells in a 100 µl suspension or 5 ul per 100 µl of whole blood. | |
| Sample-dependent, Check data in validation data gallery. | |
产品信息
FITC-65611 targets ALCAM in FC applications and shows reactivity with human samples.
| 经测试应用 | FC Application Description |
| 经测试反应性 | human |
| 免疫原 |
Cultured human thymic epithelial cells 种属同源性预测 |
| 宿主/亚型 | Mouse / IgG2a |
| 抗体类别 | Recombinant |
| 产品类型 | Antibody |
| 全称 | activated leukocyte cell adhesion molecule |
| 别名 | 3A6, CD166, MEMD |
| 计算分子量 | 105 kDa |
| GenBank蛋白编号 | BC057809 |
| 基因名称 | ALCAM |
| Gene ID (NCBI) | 214 |
| 偶联类型 | FITC Plus Fluorescent Dye |
| 最大激发/发射波长 | 495 nm / 524 nm |
| 激发激光 | Blue laser (488 nm) |
| 形式 | Liquid |
| 纯化方式 | Protein A purification |
| UNIPROT ID | Q13740 |
| 储存缓冲液 | PBS with 0.09% sodium azide and 0.5% BSA, pH 7.3. |
| 储存条件 | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
背景介绍
Activated leukocyte cell adhesion molecule (ALCAM, also known as CD166) is a cell adhesion molecule that belongs to the immunoglobulin superfamily. It is involved in cell-cell adhesion through homophilic and heterophilic (to CD6) interactions. ALCAM is widely expressed in a variety of normal tissues and cell types, including activated T cells and monocytes, epithelial cells, fibroblasts, neuronal cells, hepatocytes, and bone marrow mesenchymal stem cells (PMID: 7760007; 25221999). Altered ALCAM expression has been associated with the differentiation state and progression in some neoplasms including melanoma, prostate, colorectal, and breast cancers (PMID: 20461761; 18172759).
实验方案
| Product Specific Protocols | |
|---|---|
| FC protocol for FITC Plus ALCAM antibody FITC-65611 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
